# Galectin Therapeutics Inc: financial statements, quarterly

GALT · Nasdaq · CIK 1133416 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/galt.md) · [Financials](/companies/galt/financials.md) · [Filings](/companies/galt/filings.md) · [Insiders](/companies/galt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/galt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [7.7](/filings/0001140361-24-046726.md) | [8.2 d](/filings/0001140361-25-011169.md) | [8.1](/filings/0001140361-25-019149.md) | [9.8](/filings/0001140361-25-031039.md) | [7.6](/filings/0001140361-25-042116.md) | [11.1 d](/filings/0001140361-26-012155.md) | [6.5](/filings/0001140361-26-021495.md) | [3.3](/filings/0001140361-26-032945.md) | [2.6](/filings/0001140361-25-042116.md) | [1.9 d](/filings/0001140361-26-012155.md) | [2.2](/filings/0001140361-26-021495.md) | [2.1](/filings/0001140361-26-032945.md) |
| Operating income | $m | [(9.2)](/filings/0001140361-24-046726.md) | [(9.6) d](/filings/0001140361-25-011169.md) | [(9.6)](/filings/0001140361-25-019149.md) | [(11.3)](/filings/0001140361-25-031039.md) | [(9.1)](/filings/0001140361-25-042116.md) | [(12.4) d](/filings/0001140361-26-012155.md) | [(7.9)](/filings/0001140361-26-021495.md) | [(4.6)](/filings/0001140361-26-032945.md) | [(4.2)](/filings/0001140361-25-042116.md) | [(3.4) d](/filings/0001140361-26-012155.md) | [(4.1)](/filings/0001140361-26-021495.md) | [(4.0)](/filings/0001140361-26-032945.md) |
| Interest expense | $m | [0.8](/filings/0001140361-23-052729.md) | [0.8 d](/filings/0001140361-24-016452.md) | [1.1](/filings/0001140361-24-026105.md) | [1.3](/filings/0001140361-25-031039.md) | [1.5](/filings/0001140361-25-042116.md) | [1.7 d](/filings/0001140361-26-012155.md) | [1.7](/filings/0001140361-26-021495.md) | [1.8](/filings/0001140361-26-032945.md) | [1.8](/filings/0001140361-25-042116.md) | [1.9 d](/filings/0001140361-26-012155.md) | [2.0](/filings/0001140361-26-021495.md) | [2.0](/filings/0001140361-26-032945.md) |
| Net income | $m | [(10.4)](/filings/0001140361-24-046726.md) | [(10.0) d](/filings/0001140361-25-011169.md) | [(11.5)](/filings/0001140361-25-019149.md) | [(12.4)](/filings/0001140361-25-031039.md) | [(11.2)](/filings/0001140361-25-042116.md) | [(12.0) d](/filings/0001140361-26-012155.md) | [(9.6)](/filings/0001140361-26-021495.md) | [(7.5)](/filings/0001140361-26-032945.md) | [(8.2)](/filings/0001140361-25-042116.md) | [(5.5) d](/filings/0001140361-26-012155.md) | [(5.0)](/filings/0001140361-26-021495.md) | [(9.1)](/filings/0001140361-26-032945.md) |
| Diluted EPS | $ per share | [(0.24)](/filings/0001140361-24-046726.md) | not reported | [(0.19)](/filings/0001140361-25-019149.md) | [(0.20)](/filings/0001140361-25-031039.md) | [(0.18)](/filings/0001140361-25-042116.md) | not reported | [(0.15)](/filings/0001140361-26-021495.md) | [(0.12)](/filings/0001140361-26-032945.md) | [(0.13)](/filings/0001140361-25-042116.md) | not reported | [(0.08)](/filings/0001140361-26-021495.md) | [(0.14)](/filings/0001140361-26-032945.md) |
| Basic EPS | $ per share | [(0.24)](/filings/0001140361-24-046726.md) | not reported | [(0.19)](/filings/0001140361-25-019149.md) | [(0.20)](/filings/0001140361-25-031039.md) | [(0.18)](/filings/0001140361-25-042116.md) | not reported | [(0.15)](/filings/0001140361-26-021495.md) | [(0.12)](/filings/0001140361-26-032945.md) | [(0.13)](/filings/0001140361-25-042116.md) | not reported | [(0.08)](/filings/0001140361-26-021495.md) | [(0.14)](/filings/0001140361-26-032945.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [20.4](/filings/0001140361-23-052729.md) | [25.7](/filings/0001140361-25-011169.md) | [23.6](/filings/0001140361-24-026105.md) | [25.6](/filings/0001140361-24-036937.md) | [27.1](/filings/0001140361-24-046726.md) | [15.1](/filings/0001140361-26-012155.md) | [7.4](/filings/0001140361-25-019149.md) | [13.8](/filings/0001140361-25-031039.md) | [11.5](/filings/0001140361-25-042116.md) | [17.7](/filings/0001140361-26-032945.md) | [14.1](/filings/0001140361-26-021495.md) | [13.3](/filings/0001140361-26-032945.md) |
| Current assets | $m | [21.6](/filings/0001140361-23-052729.md) | [27.7](/filings/0001140361-25-011169.md) | [25.5](/filings/0001140361-24-026105.md) | [27.3](/filings/0001140361-24-036937.md) | [28.7](/filings/0001140361-24-046726.md) | [17.3](/filings/0001140361-26-012155.md) | [9.3](/filings/0001140361-25-019149.md) | [15.4](/filings/0001140361-25-031039.md) | [12.7](/filings/0001140361-25-042116.md) | [19.4](/filings/0001140361-26-032945.md) | [15.7](/filings/0001140361-26-021495.md) | [14.7](/filings/0001140361-26-032945.md) |
| Total assets | $m | [22.2](/filings/0001140361-23-052729.md) | [28.2](/filings/0001140361-25-011169.md) | [25.9](/filings/0001140361-24-026105.md) | [27.7](/filings/0001140361-24-036937.md) | [29.0](/filings/0001140361-24-046726.md) | [17.5](/filings/0001140361-26-012155.md) | [9.5](/filings/0001140361-25-019149.md) | [15.6](/filings/0001140361-25-031039.md) | [12.9](/filings/0001140361-25-042116.md) | [19.5](/filings/0001140361-26-032945.md) | [15.8](/filings/0001140361-26-021495.md) | [14.8](/filings/0001140361-26-032945.md) |
| Current liabilities | $m | [10.5](/filings/0001140361-23-052729.md) | [15.7](/filings/0001140361-25-011169.md) | [12.6](/filings/0001140361-24-026105.md) | [14.6](/filings/0001140361-24-036937.md) | [25.3](/filings/0001140361-24-046726.md) | [35.4](/filings/0001140361-26-012155.md) | [111](/filings/0001140361-25-019149.md) | [10.8](/filings/0001140361-25-031039.md) | [136](/filings/0001140361-25-042116.md) | [8.0](/filings/0001140361-26-032945.md) | [7.3](/filings/0001140361-26-021495.md) | [152](/filings/0001140361-26-032945.md) |
| Total liabilities | $m | [73.0](/filings/0001140361-23-052729.md) | [88.4](/filings/0001140361-25-011169.md) | [97.0](/filings/0001140361-24-026105.md) | [110](/filings/0001140361-24-036937.md) | [121](/filings/0001140361-24-046726.md) | [121](/filings/0001140361-26-012155.md) | [122](/filings/0001140361-25-019149.md) | [133](/filings/0001140361-25-031039.md) | [136](/filings/0001140361-25-042116.md) | [146](/filings/0001140361-26-032945.md) | [146](/filings/0001140361-26-021495.md) | [152](/filings/0001140361-26-032945.md) |
| Shareholders' equity | $m | [(52.6)](/filings/0001140361-24-046726.md) | [(62.0)](/filings/0001140361-26-012155.md) | [(44.4)](/filings/0001140361-25-031039.md) | [(83.9)](/filings/0001140361-25-042116.md) | [(94.2)](/filings/0001140361-25-042116.md) | [(105)](/filings/0001140361-26-032945.md) | [(114)](/filings/0001140361-26-032945.md) | [(119)](/filings/0001140361-26-032945.md) | [(125)](/filings/0001140361-25-042116.md) | [(128)](/filings/0001140361-26-032945.md) | [(132)](/filings/0001140361-26-032945.md) | [(139)](/filings/0001140361-26-032945.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.6) d](/filings/0001140361-24-046726.md) | [(4.7) d](/filings/0001140361-25-011169.md) | [(12.1)](/filings/0001140361-25-019149.md) | [(8.3) d](/filings/0001140361-25-031039.md) | [(8.5) d](/filings/0001140361-25-042116.md) | [(12.8) d](/filings/0001140361-26-012155.md) | [(7.7)](/filings/0001140361-26-021495.md) | [(6.6) d](/filings/0001140361-26-032945.md) | [(3.5) d](/filings/0001140361-25-042116.md) | [(6.0) d](/filings/0001140361-26-012155.md) | [(3.9)](/filings/0001140361-26-021495.md) | [(2.4) d](/filings/0001140361-26-032945.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [59.4](/filings/0001140361-23-052729.md) | [59.5](/filings/0001140361-24-026105.md) | [59.6](/filings/0001140361-24-036937.md) | [59.7](/filings/0001140361-24-046726.md) | [62.0](/filings/0001140361-25-019149.md) | [62.2](/filings/0001140361-25-031039.md) | [62.3](/filings/0001140361-25-042116.md) | [63.2](/filings/0001140361-26-021495.md) | [63.4](/filings/0001140361-26-032945.md) | [64.2](/filings/0001140361-25-042116.md) | [65.8](/filings/0001140361-26-021495.md) | [65.9](/filings/0001140361-26-032945.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 100,849,644 at 2026-08-06, from the cover of the [10-Q filed 2026-08-14](/filings/0001140361-26-032945.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.